| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 07/22/2014 | US8785143 Method for immobilizing streptavidin on a self-assembled monolayer |
| 07/22/2014 | US8784843 Stabilizers for freeze-dried vaccines |
| 07/22/2014 | US8784842 Allelic exchange mutagenesis in Map |
| 07/22/2014 | US8784841 Therapeutic use of at least one botulinum neurotoxin in the treatment of pain associated with diabetic neuropathy |
| 07/22/2014 | US8784840 Method for screening modulators of apoptosis |
| 07/22/2014 | US8784839 Attenuated live vaccines |
| 07/22/2014 | US8784838 H3 influenza A virus |
| 07/22/2014 | US8784837 Vaccines comprising an immunostimulatory peptide and an immunostimulatory oligodeoxynucleic acid molecule |
| 07/22/2014 | US8784836 Microorganisms for therapy |
| 07/22/2014 | US8784834 Recombinant fusion interferon for animals |
| 07/22/2014 | US8784833 Prenatal enzyme replacement therapy for hypophosphatasia |
| 07/22/2014 | US8784832 Synthetic antigen based on the ligand domain of the Plasmodium vivax duffy binding protein |
| 07/22/2014 | US8784831 P. gingivalis antigenic composition |
| 07/22/2014 | US8784830 Antigen peptide and use thereof |
| 07/22/2014 | US8784829 Lawsonia intracellularis vaccines |
| 07/22/2014 | US8784828 Ehrlichia ewingii proteins, nucleic acids, and methods of their use |
| 07/22/2014 | US8784827 Chimeric fusion proteins and virus like particles from Birnavirus VP2 |
| 07/22/2014 | US8784826 Multiple vaccination including serogroup C meningococcus |
| 07/22/2014 | US8784825 Modulators of MYC, methods of using the same, and methods of identifying agents that modulate MYC |
| 07/22/2014 | US8784824 Compositions and methods for treatment of angiogenesis in pathological lesions |
| 07/22/2014 | US8784823 Binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind CD154 and uses thereof |
| 07/22/2014 | US8784822 Method and composition for treatment of renal failure with antibodies and their equivalents as partial or complete replacement for dialysis |
| 07/22/2014 | US8784820 Plasminogen-activating antibody, use and producing method thereof and agent including the same |
| 07/22/2014 | US8784819 Influenza hemagglutinin antibodies, compositions and related methods |
| 07/22/2014 | US8784818 Anti-VEGFR-3 antibody compositions |
| 07/22/2014 | US8784817 Method for killing IL-1 alpha expressing cells |
| 07/22/2014 | US8784816 Antibodies which bind factor VIII |
| 07/22/2014 | US8784815 Human CTLA-4 antibodies and their uses |
| 07/22/2014 | US8784814 Method for inhibiting binding to B-cell receptor |
| 07/22/2014 | US8784813 L-amino acid oxidase with cytotoxic activity from Aplysia punctata |
| 07/22/2014 | US8784812 Methods for treating autoimmune diseases using a TACI-Ig fusion molecule |
| 07/22/2014 | US8784811 Method of treating cancer using antibodies to a non-ligand binding region of NOTCH1 |
| 07/22/2014 | US8784810 Treatment of amyloidogenic diseases |
| 07/22/2014 | US8784809 Vascular endothelial growth factor 2 |
| 07/22/2014 | US8784808 FcγRIIB specific antibodies and methods of use thereof |
| 07/22/2014 | US8784807 Method of inhibiting regulatory T-cell activity by administering an antibody that inhibits interleukin 35 |
| 07/22/2014 | US8784799 Duplexed parvovirus vectors |
| 07/22/2014 | US8784796 Vaccine immunotherapy for treating hepatocellular cancer in immune suppressed patients |
| 07/22/2014 | US8784776 Use of FSH receptor ligands for diagnosis and therapy of cancer |
| 07/22/2014 | US8784772 Urothelial differentiation of urothelial carcinoma: a bladder cancer stem cell model |
| 07/22/2014 | US8784385 Frozen piercing implements and methods for piercing a substrate |
| 07/22/2014 | CA2573144C Methods for treating conditions associated with masp-2 dependent complement activation |
| 07/22/2014 | CA2537742C Immunogenic compositions for streptococcus agalactiae |
| 07/22/2014 | CA2524883C Potassium-chloride cotransporter kcc2 modulation for treatment of pain |
| 07/22/2014 | CA2494756C Anti-tnf-alpha antibodies in solution and uses thereof |
| 07/22/2014 | CA2441809C Lipsomal vaccines comprising dilipopetides for modulating t1 and t2 immune responses |
| 07/22/2014 | CA2412845C Enhancement of antibody-cytokine fusion protein mediated immune responses by combined treatment with immunocytokine uptake enhancing agents |
| 07/22/2014 | CA2405299C Method of treatment using ligand-immunogen conjugates |
| 07/22/2014 | CA2388562C Mammalian cytokines; related reagents and methods |
| 07/17/2014 | WO2014110506A2 Methods of treating, preventing and diagnosing leukemia and other blood diseases and disorders |
| 07/17/2014 | WO2014110438A1 Compounds and methods related to the c5d domain of complement component c5 |
| 07/17/2014 | WO2014110368A1 Bovine fusion antibodies |
| 07/17/2014 | WO2014110243A1 Method for treating pulmonary hypertension |
| 07/17/2014 | WO2014110092A1 Methods of generating robust passive and active immune responses |
| 07/17/2014 | WO2014110081A1 Immune regulatory oligonucleotide (iro) compounds to modulate toll-like receptor based immune response |
| 07/17/2014 | WO2014110053A1 Use of inos inhibitors to increase viral yield in culture |
| 07/17/2014 | WO2014109999A1 ANTI-PDGFR-beta ANTIBODIES AND USES THEREOF |
| 07/17/2014 | WO2014109927A1 Synthesis and isolation of dendrimer based imaging systems |
| 07/17/2014 | WO2014108829A1 New antibody fragments, compositions and uses thereof |
| 07/17/2014 | WO2014108707A1 Identification of patients for breast cancer theraphy using t128 family members as markers |
| 07/17/2014 | WO2014108515A1 Influenza virus immunogenic compositions and uses thereof |
| 07/17/2014 | WO2014108497A2 Vaccine |
| 07/17/2014 | WO2014108456A1 Use of antibodies against icam-1 in combination with an anti cancer drug in the treatment of patients |
| 07/17/2014 | WO2014108198A1 Human igg1 fc region variants and uses thereof |
| 07/17/2014 | WO2014074535A3 Flavivirus envelope protein mutations affecting virion disassembly |
| 07/17/2014 | WO2014058924A9 Antibodies recognizing alpha-synuclein |
| 07/17/2014 | WO2014053521A3 Nonlinear saccharide conjugates |
| 07/17/2014 | WO2014045191A3 Extracellular polysaccharides from labyrinthulomycetes with broad-spectrum antiviral activities |
| 07/17/2014 | WO2014020290A3 Use of attenuated strains of toxoplasma for the prevention or treatment of cryptosporidiosis |
| 07/17/2014 | WO2013091898A8 Method for producing high yield attenuated salmonella strains |
| 07/17/2014 | WO2013059885A3 Polypeptide constructs and uses thereof |
| 07/17/2014 | WO2012156532A8 Anti-human-her3 antibodies and uses thereof |
| 07/17/2014 | US20140200516 Buccal, polar and non-polar spray or capsule containing drugs for treating metabolic disorders |
| 07/17/2014 | US20140200332 Low dose methods for treating disorders in which tnf-alpha activity is detrimental |
| 07/17/2014 | US20140199399 Use of tgf-beta antagonists to treat infants at risk of developing bronchopulmonary dysplasia |
| 07/17/2014 | US20140199389 Enteric active substance delivery |
| 07/17/2014 | US20140199379 Compositions having means for targeting at least one antigen to dendritic cells |
| 07/17/2014 | US20140199376 Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations thereof |
| 07/17/2014 | US20140199350 Chimeric topical vaccine for haemophilus influenzae-induced disease |
| 07/17/2014 | US20140199347 Adjuvant compositions with 4-1bbl |
| 07/17/2014 | US20140199346 Therapeutic agent for influenza virus infection diseases |
| 07/17/2014 | US20140199344 Anti-measles cancer immunotherapy |
| 07/17/2014 | US20140199343 Recombinant vaccine against prrs in a viral vector |
| 07/17/2014 | US20140199340 Tolerogenic synthetic nanocarriers for inducing regulatory b cells |
| 07/17/2014 | US20140199339 Compositions and methods for inducing immune responses against bacteria in the genus staphylococcus |
| 07/17/2014 | US20140199338 Vaccines for protection from and treatment of alzheimer's disease |
| 07/17/2014 | US20140199337 Influenza h5 vaccines |
| 07/17/2014 | US20140199333 Aquaporin-4 Peptides, Compositions and Methods of Use |
| 07/17/2014 | US20140199332 Method of treating cancer with an hla-a*3303-restricted wt1 peptide and pharmaceutical composition comprising the same |
| 07/17/2014 | US20140199329 Methods for treating and preventing neutrophil-derived net toxicity and thrombosis |
| 07/17/2014 | US20140199323 Monoclonal Antibody |
| 07/17/2014 | US20140199322 Transdiscal Administration of Specific Inhibitors of Pro-Inflammatory Cytokines |
| 07/17/2014 | US20140199321 Stabilizing polypeptides which have been exposed to urea |
| 07/17/2014 | US20140199313 Process for the Production of Fine Chemicals |
| 07/17/2014 | US20140199312 DDR1-Binding Agents and Methods of Use Thereof |
| 07/17/2014 | US20140199311 Pharmaceutical composition for treatment and/or prophylaxis of cancer |
| 07/17/2014 | US20140199310 Compositions comprising agents that inhibit neuropilin and tolloid like 2 |
| 07/17/2014 | US20140199308 Compositions and methods to enhance the immune system |
| 07/17/2014 | US20140199303 Stable Liquid Formulation of Etanercept |
| 07/17/2014 | US20140199300 Combination therapy for the treatment of cd19+ b-cell malignancies symptoms comprising an anti-cd1 maytansinoid immunoconjugate and rituzimab |